Log in

OTCMKTS:CMXCCell MedX Stock Price, Forecast & News

+0.02 (+2.63 %)
(As of 07/7/2020 04:00 PM ET)
Today's Range
Now: $0.59
50-Day Range
MA: $0.61
52-Week Range
Now: $0.59
Volume35,663 shs
Average Volume73,267 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Cell MedX Corp., a development stage company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, and high blood pressure. It also develops and manufactures eBalance technology that is in the research and development stage to manage diabetes mellitus and its complications. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada. Cell MedX Corp. is a subsidiary of Wisdom Homes of America, Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars

Industry, Sector and Symbol

Industry Conglomerates
Current SymbolOTCMKTS:CMXC
Previous SymbolNASDAQ:CMXC



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive CMXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CMXC and its competitors with MarketBeat's FREE daily newsletter.

Cell MedX (OTCMKTS:CMXC) Frequently Asked Questions

How has Cell MedX's stock been impacted by COVID-19 (Coronavirus)?

Cell MedX's stock was trading at $0.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CMXC shares have increased by 88.7% and is now trading at $0.5850. View which stocks have been most impacted by Coronavirus.

Has Cell MedX been receiving favorable news coverage?

News stories about CMXC stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cell MedX earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Cell MedX.

Who are some of Cell MedX's key competitors?

What other stocks do shareholders of Cell MedX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cell MedX investors own include Callon Petroleum (CPE), Himax Technologies (HIMX), Remark (MARK), Microvision (MVIS), Ritter Pharmaceuticals (RTTR), CytoDyn (CYDY), Linn Energy (LINEQ), Audioeye (AEYE), AmpliPhi Biosciences (ARMP) and Bank of America (BAC).

Who are Cell MedX's key executives?

Cell MedX's management team includes the following people:
  • Mr. Frank E. McEnulty, CEO & Director (Age 63)
  • Ms. Yanika Silina C.M.A., CPA, CFO, Treasurer, Corp. Sec. & Director (Age 41)
  • Mr. Bradley S. Hargreaves, VP of Technology & Operations and Director (Age 60)

What is Cell MedX's stock symbol?

Cell MedX trades on the OTCMKTS under the ticker symbol "CMXC."

How do I buy shares of Cell MedX?

Shares of CMXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cell MedX's stock price today?

One share of CMXC stock can currently be purchased for approximately $0.59.

What is Cell MedX's official website?

The official website for Cell MedX is cellmedx.com.

How can I contact Cell MedX?

Cell MedX's mailing address is 123 W Nye Ln Ste 446, CARSON CITY, NV 89706-0899, United States. The company can be reached via phone at +1-310-5089398.

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.